Score Predicting Lesion Development on CT Following Mild TBI
Launched by KAROLINSKA INSTITUTET · Aug 4, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying mild traumatic brain injury (mTBI), which is a common reason for people to visit the emergency room. The main goal of the trial is to create a scoring system that can help predict whether a patient with mTBI might develop serious brain injuries that could require surgery. Researchers will look at data from adults aged 15 and older who visited the emergency department in Stockholm, Sweden, within 24 hours of their injury and had a specific level of consciousness. They will use advanced computer models to analyze the information collected from these patients.
To participate in this study, individuals must meet certain criteria: they need to be 15 years or older, have come to the emergency department shortly after their injury, and have a specific score that indicates their level of consciousness. Participants will undergo a CT scan to check for any brain injuries. The findings from this study could help improve how doctors assess and treat patients with mTBI in the future, making it easier to identify those who may need further medical attention.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (≥ 15 years)
- • Presented to emergency department within 24 hours of TBI
- • GCS 13-15 at presentation to the emergency department
- Exclusion Criteria:
- • No CT scan performed
- • Patient from another Region in Sweden/another country
- • Penetrating TBI
- • Secondary transfer from other emergency department
- • Medical record missing
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, Other, Sweden
Patients applied
Trial Officials
Eric P Thelin, MD, PhD
Principal Investigator
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials